A La CaRT: Australasian Laparoscopic Cancer Of The Rectum Trial. A Phase III Prospective Randomised Trial Comparing Laparoscopic-assisted Resection Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$599,054.00
Summary
The major treatment for rectal cancer is surgical removal of tumour with a large cut through the abdomen. There is a newer, less invasive procedure known as laparoscopic resection which enables the same surgery to be performed using a scope inserted in the abdomen and another smaller incision for removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure. Patients on the trial will be given either laparoscopi
Targeting Prostate Cancer And Metastases With Novel Anti-tumour Drugs.
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
Prostate cancer is highly aggressive, causing one death every 4 minutes. It is the most common tumour and is the second highest cause of cancer death in men in Western society. Once it escapes the prostate and spreads to other parts of the body it cannot be cured. Current treatment options are limited and cause debilitating side effects. In this study I will investigate a new class of anticancer drugs developed in my host laboratory for prostate cancer treatment.
Prospective Ovarian Cancer Cohort To Authenticate Stratification Of Prognosis In Ovarian Tumours (POCCA-SPOT)
Funder
National Health and Medical Research Council
Funding Amount
$993,580.00
Summary
Ovarian cancer has poor survival, with less than 40% of women surviving 5 years. There is a wide range of survival, but very few characteristics that indicate which patients will do well or poorly. We have developed a tumour test at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we will test tumours to predict prognosis and then determine the accuracy and assess patient acceptability. This study will lead to clinical use of the test and improve treatment decisions.
This project aims to comprehensively evaluate the role of androgen receptor (AR) signalling in breast cancer by identifying changes in AR signalling and its role in an endocrine resistant setting. Understanding the changes in AR signalling in either treatment-naive or treatment-resistant context would better assist in the identification for opportunities to modulate AR signalling as a therapeutic target in breast cancer.
Indwelling Pleural Catheter For Management Of Cancer-related Pleural Effusions
Funder
National Health and Medical Research Council
Funding Amount
$123,688.00
Summary
Most cancers can be complicated by fluid accumulation (effusion) in the (pleural) cavity between the lung and chest wall, causing significant breathlessness. Indwelling pleural catheter (IPC) is a new method that allows patients to drain the effusion outside the hospital and avoid further invasive interventions. This study aims to provide important information that will help guide use of IPC and manage its complications, especially infection, improve patient outcomes and save healthcare costs.
Microfluidic Strategy For Circulating Tumour Cells Analysis In Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$429,180.00
Summary
My approach and ultimate goal over the next 4 years is to demonstrate the use of recently discovered “Nanoshearing” technology as a standard diagnostic tool for cancer patients undergoing systemic therapy and assess the impact of standard protocols in predicting response to therapy and patient outcomes. Data from this study could potentially define new standards of clinical practice, as they relate to follow-up screening for response to therapy and recurrence of disease.
Massively Parallel Sequencing And PCR Optimised For DNA-based Diagnostics And Discovery
Funder
National Health and Medical Research Council
Funding Amount
$201,664.00
Summary
The next generation of medical diagnostics and discovery in disease research will involve the marriage of PCR, a tool used to amplify large amounts of DNA from small starting quantities, and �next generation� sequencing, a way to sequence lots and lots of DNA on a single instrument run. This study aims to describe methods which allow scientists to screen hundreds of disease genes in hundreds of people simultaneously with high accuracy and high efficiency.
ALT-associated PML Bodies: Keys To The Biology And Treatment Of An Important Subset Of Cancers
Funder
National Health and Medical Research Council
Funding Amount
$813,614.00
Summary
Alternative Lengthening of Telomeres (ALT) is a molecular mechanism used by ~10% of cancers to sustain their relentless growth. ALT is common in sarcomas and brain tumours which are difficult to treat. ALT cancers contain nuclear structures called ALT-associated PML nuclear bodies (APBs) which may be part of the ALT machinery. This research will investigate characteristics of APBs and how they are formed, and will use this information to identify drugs to treat ALT tumours.
Testing And Treatment For Prostate Cancer In Australia: Epidemiology And Modelling
Funder
National Health and Medical Research Council
Funding Amount
$267,886.00
Summary
We aim to use observational data and mathematical modelling to investigate testing and treatment for prostate cancer in Australia. We will incorporate changes in prostate-specific antigen (PSA) testing and in clinical practice to investigate: a) over-diagnosis, being cancer cases diagnosed through PSA testing that would not have been otherwise diagnosed; b) the effect of PSA testing on prostate cancer mortality; and c) mortality and health care use under different PSA test scenarios.
Engineering MYCN Models Of High-grade Serous Ovarian Cancer (HGSC)
Funder
National Health and Medical Research Council
Funding Amount
$797,478.00
Summary
The most lethal type of ovarian cancer, high-grade serous cancer (HGSC), can be divided into four subtypes based on gene patterns. One subtype involves a set of genes/proteins that, in their specific combination, result in activation of a pathway known as MYCN. As most HGSC start in the fallopian tube, we are using fallopian tube material to make new MYCN HGSC models to observe development in the earliest stages. We hope to generate new tests and treatments for this subtype of ovarian cancer.